$2500 | Single User
$4500 | Enterprise License

AIDS-Pricing & Market Access and Landscape- 2019
[Lowest Price Guaranteed: $2,500]

Published by First View Insight: 15 Nov 2019 | 238842 | In Stock
Related Topics: Pricing

Introduction

Firstview Insight's AIDS-Pricing & Market Access and Landscape- 2019 provides country specific insights in order to estimate market potential forAIDS based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing & Market Access landscape.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection, making a person more vulnerable to other infections and diseases. It is spread by contact with certain bodily fluids of a person with HIV, most commonly during unprotected sex (sex without a condom or HIV medicine to prevent or treat HIV), or through sharing injection drug equipment. If left untreated, HIV can lead to the disease AIDS (acquired immunodeficiency syndrome).

AIDS is the late stage of HIV infection that occurs when the body’s immune system is badly damaged because of the virus. In the U.S., most people with HIV do not develop AIDS because taking HIV medicine every day as prescribed stops the progression of the disease.

Scope of the Report:

Market Access strategy for different payer archetypes

Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. cost-effectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.

Payer Policy changes and implications

Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.

Innovative pricing and funding mechanisms

With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.

Disease Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines

Epidemiology

This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan.

Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.

Market Trends & Unmet needs

This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

Major highlights of the report

Detailed analysis of existing and upcoming competitive landscape

HTA decisions and benefit ratings for :

NICE (UK)

GBA (Germany)

HAS(ASMR and SMR)(France)

AIFA (Italy)

AEMPS (Spain)

SMC (Scotland)

ICER (US)

Chuikyo (Japan)

Market archetyping and product positioning

Case studies on innovative funding models

Unmet need, major barriers and drivers across the industry:

Value story for achieving reimbursement and premium pricing in different markets

Table of Contents
for AIDS-Pricing & Market Access and Landscape- 2019

  • 1. Disease overview

    1.1. Pathophysiology

    1.2. Symptoms

    1.3. Etiology

    1.4. Diagnosis

    1.5. Treatment Algorithm

    1.6. Treatment Options

    2. Overview of Marketed drugs

    2.1 Prezista

    2.1.1. Drug description

    2.1.2. Mechanism of action

    2.1.3 Clinical trials and regulatory milestones

    2.1.4 Pricing and market access landscape

    2.1.5 Pricing and market access drivers

    2.1.6 Adverse events

    2.2 Stocrin

    2.2.1. Drug description

    2.2.2. Mechanism of action

    2.2.3 Clinical trials and regulatory milestones

    2.2.4 Pricing and market access landscape

    2.2.5 Pricing and market access drivers

    2.2.6 Adverse events

    2.3 Complera

    2.3.1. Drug description

    2.3.2. Mechanism of action

    2.3.3 Clinical trials and regulatory milestones

    2.3.4 Pricing and market access landscape

    2.3.5 Pricing and market access drivers

    2.3.6 Adverse events

    2.4 Kiovig

    2.4.1. Drug description

    2.4.2. Mechanism of action

    2.4.3 Clinical trials and regulatory milestones

    2.4.4 Pricing and market access landscape

    2.4.5 Pricing and market access drivers

    2.4.6 Adverse events

    2.5 Symtuza

    2.5.1. Drug description

    2.5.2. Mechanism of action

    2.5.3 Clinical trials and regulatory milestones

    2.5.4 Pricing and market access landscape

    2.5.5 Pricing and market access drivers

    2.5.6 Adverse events

    2.6 Isentress

    2.6.1. Drug description

    2.6.2. Mechanism of action

    2.6.3 Clinical trials and regulatory milestones

    2.6.4 Pricing and market access landscape

    2.6.5 Pricing and market access drivers

    2.6.6 Adverse events

    2.7 Invirase

    2.7.1. Drug description

    2.7.2. Mechanism of action

    2.7.3 Clinical trials and regulatory milestones

    2.7.4 Pricing and market access landscape

    2.7.5 Pricing and market access drivers

    2.7.6 Adverse events

    2.8 Eviplera

    2.8.1. Drug description

    2.8.2. Mechanism of action

    2.8.3 Clinical trials and regulatory milestones

    2.8.4 Pricing and market access landscape

    2.8.5 Pricing and market access drivers

    2.8.6 Adverse events

    2.9 Emtriva

    2.9.1. Drug description

    2.9.2. Mechanism of action

    2.9.3 Clinical trials and regulatory milestones

    2.9.4 Pricing and market access landscape

    2.9.5 Pricing and market access drivers

    2.9.6 Adverse events

    2.10 Reyataz

    2.10.1. Drug description

    2.10.2. Mechanism of action

    2.10.3 Clinical trials and regulatory milestones

    2.10.4 Pricing and market access landscape

    2.10.5 Pricing and market access drivers

    2.10.6 Adverse events

    2.11 Combivir

    2.11.1. Drug description

    2.11.2. Mechanism of action

    2.11.3 Clinical trials and regulatory milestones

    2.11.4 Pricing and market access landscape

    2.11.5 Pricing and market access drivers

    2.11.6 Adverse events

    2.12 Kivexa

    2.12.1. Drug description

    2.12.2. Mechanism of action

    2.12.3 Clinical trials and regulatory milestones

    2.12.4 Pricing and market access landscape

    2.12.5 Pricing and market access drivers

    2.12.6 Adverse events

    2.13 Edurant

    2.13.1. Drug description

    2.13.2. Mechanism of action

    2.13.3 Clinical trials and regulatory milestones

    2.13.4 Pricing and market access landscape

    2.13.5 Pricing and market access drivers

    2.13.6 Adverse events

    2.14 Tivicay

    2.14.1. Drug description

    2.14.2. Mechanism of action

    2.14.3 Clinical trials and regulatory milestones

    2.14.4 Pricing and market access landscape

    2.14.5 Pricing and market access drivers

    2.14.6 Adverse events

    2.15 Delstrigo

    2.15.1. Drug description

    2.15.2. Mechanism of action

    2.15.3 Clinical trials and regulatory milestones

    2.15.4 Pricing and market access landscape

    2.15.5 Pricing and market access drivers

    2.15.6 Adverse events

    2.16 Triumeq

    2.16.1. Drug description

    2.16.2. Mechanism of action

    2.16.3 Clinical trials and regulatory milestones

    2.16.4 Pricing and market access landscape

    2.16.5 Pricing and market access drivers

    2.16.6 Adverse events

    2.17 Tybost

    2.17.1. Drug description

    2.17.2. Mechanism of action

    2.17.3 Clinical trials and regulatory milestones

    2.17.4 Pricing and market access landscape

    2.17.5 Pricing and market access drivers

    2.17.6 Adverse events

    2.18 Celsentri

    2.18.1. Drug description

    2.18.2. Mechanism of action

    2.18.3 Clinical trials and regulatory milestones

    2.18.4 Pricing and market access landscape

    2.18.5 Pricing and market access drivers

    2.18.6 Adverse events

    3. Overview of Major Pipeline Drugs

    4. Summary of Pricing & Market Access landscape in USA, EU5, Australia and Canada

    5. Pricing of drugs in major markets

    6. Market Access strategy for different payer archetypes

    7. Drivers and Barriers

    8. Unmet Needs

    9. Innovative pricing and funding mechanisms

    10. Appendix

    11. Report Methodology

    12. Consulting Services

    13. Disclaimer

List Of Tables
in AIDS-Pricing & Market Access and Landscape- 2019

Table 1: List of Marketed Drugs for AIDS

Table 2: Market access landscape of Prezista

Table 3: Market access landscape of Stocrin

Table 4: Market access landscape of Complera

Table 5: Market access landscape of Kiovig

Table 6: Market access landscape of Symtuza

Table 7: Market access landscape of Isentress

Table 8: Market access landscape of Invirase

Table 9: Major pipeline drugs

Table 10: Drivers and access barries

List Of Figures, Charts and Diagrams
in AIDS-Pricing & Market Access and Landscape- 2019

Figure 1: Prices of therapies indicated for AIDS in France

Figure 2: Prices of therapies indicated for AIDS in UK

Figure 3: Prices of therapies indicated for AIDS in Italy

Figure 4: Prices of therapies indicated for AIDS in Germany

Figure 5: Prices of therapies indicated for AIDS in Italy

Figure 6: Prices of therapies indicated for AIDS in Spain

Figure 7: Prices of therapies indicated for AIDS in USA

Figure 8: Prices of therapies indicated for AIDS in Canada

Figure 9: Prices of therapies indicated for AIDS in Australia

Additional Details

Publisher

First View Insight

Publisher Information

Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.



About FirstView Insight



FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Reference

238842 |

Number of Pages

340

Report Format

PDF

First View Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global AIDS Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
International AIDS Vaccine Initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryInternational AIDS Vaccine Initiative (IAVI) is a not-for-profit organization that focuses on...
27 Apr 2016 by Global Data USD $250 More Info
International AIDS Vaccine Initiative - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryInternational AIDS Vaccine Initiative (IAVI) is a not-for-profit organization that focuses on...
14 Mar 2016 by Global Data USD $250 More Info
United States Mobility Aids and Transportation Equipment Market Outlook to 2021
United States Mobility Aids and Transportation Equipment Market Outlook to 2021SummaryGlobalData’s n...
14 Mar 2016 by Global Data USD $2,500 More Info
United Kingdom Mobility Aids and Transportation Equipment Market Outlook to 2021
United Kingdom Mobility Aids and Transportation Equipment Market Outlook to 2021SummaryGlobalData’s ...
14 Mar 2016 by Global Data USD $2,500 More Info
France Mobility Aids and Transportation Equipment Market Outlook to 2021
France Mobility Aids and Transportation Equipment Market Outlook to 2021SummaryGlobalData’s new repo...
14 Mar 2016 by Global Data USD $2,500 More Info
Germany Mobility Aids and Transportation Equipment Market Outlook to 2021
Germany Mobility Aids and Transportation Equipment Market Outlook to 2021SummaryGlobalData’s new rep...
14 Mar 2016 by Global Data USD $2,500 More Info
Italy Mobility Aids and Transportation Equipment Market Outlook to 2021
Italy Mobility Aids and Transportation Equipment Market Outlook to 2021SummaryGlobalData’s new repor...
14 Mar 2016 by Global Data USD $2,500 More Info
Spain Mobility Aids and Transportation Equipment Market Outlook to 2021
Spain Mobility Aids and Transportation Equipment Market Outlook to 2021SummaryGlobalData’s new repor...
14 Mar 2016 by Global Data USD $2,500 More Info
Mobility Aids and Transportation Equipment - Medical Devices Pipeline Assessment, 2016
Mobility Aids and Transportation Equipment - Medical Devices Pipeline Assessment, 2016SummaryGlobalD...
11 Mar 2016 by Global Data USD $2,500 More Info

This report is published by First View Insight

Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.

About FirstView Insight

FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

Download Free Report Summary PDF

AIDS-Pricing & Market Access and Landscape- 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...